{"groups":[{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"FG000","title":"HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2"},{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"FG001","title":"HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2"},{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"FG002","title":"HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2"},{"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"FG003","title":"HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2"},{"description":"This is the phase 2 arm that was treated at the MTD determined in the phase 1 portion.\n\npatients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"FG004","title":"HPV-16 E6 mTCR PBL MTD + HD IL-2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"2"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Drug Administration"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"comment":"Patient originally started in Grp1(HPV-16 E6mTCR PBL 1x10\\^9+HD IL-2) and was retreated at the MTD.","groupId":"FG004","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Retreated at the MTD"}]}